🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07316088
Active, not recruiting Phase 2

Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms

NCT07316088 · tracked via the Priya Life Science USA tracker
Sponsor
Oui Therapeutics, Inc.
Phase
Phase 2
Started
2025-12-09
Last updated
2026-07-15

Condition(s) studied

PTSDPost Traumatic Stress Disorder

Investigational drug(s) / intervention(s)

OTX-601 Digital TherapeuticOTX-003 Comparator app

OTX-601 Digital Therapeutic: Prescription digital therapeutic designed to overcome existing barriers and deliver evidence-based treatment for PTSD

OTX-003 Comparator app: Comparator designed to match interface of intervention while providing no active treatment.

Study summary

This study is exploring the efficacy of a digital therapeutic app in reducing symptoms of posttraumatic stress disorder (PTSD) in adults.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Posttraumatic stress disorder (PTSD) diagnosis * Anxiety Sensitivity Index 3 (ASI-3) scores above 24 * PTSD Checklist for DSM-V (PCL-5) scores above 30 * Understands and speaks English * Access to a smartphone that is connected to the internet Exclusion Criteria: * Score of 24 or lower on the ASI-3 * Score of 30 and below on the PCL-5 * No PTSD diagnosis * Active psychosis * Acute intoxication during study baseline * Enrolled in another treatment research study * Medical illness that would prevent the completion of interoceptive exposure exercises

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Florida State University Tallahassee Florida

More Oui Therapeutics, Inc. trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07316088 on ClinicalTrials.gov ↗ ← All trials in the USA